Hikma receives FDA approval for Leucovorin Calcium Injection

London, 04 May 2016 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its supplemental Abbreviated New Drug Application (sANDA) for Leucovorin Calcium Injection, 350 mg Single-use vial has been approved by the U.S. Food and Drug Administration (FDA).

Press Release Product 4 May 2016

Leucovorin Calcium Injection is used for the prevention and treatment of certain blood cell disorders, and can be used in conjunction with other oncology drugs for the treatment of colorectal cancer. According to IMS Health, U.S. sales of Leucovorin Calcium Injection were approximately $35 million for the 12 months ending March 2016, of which the 350 mg presentation represented around $19 million.
Said Darwazah, Chairman and CEO of Hikma, said, “We are very pleased this product has been approved for the US market. We continue to leverage our strong R&D, regulatory and high-quality manufacturing capabilities and remain committed to prioritising the re-introduction of Bedford products for patients in need.”

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.